Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.

被引：0
|
作者：
Ochenduszko, Sebastian
Garcia, Javier
Juan-Fita, Maria Jose
Gonzalez-Barrallo, Ines
Colomina, Julio Herrero
Beveridge, Robert Diaz
Martinez, Silverio Ros
Lafuente, Blanca Sanchez
Tomas, Alberto Jacobo Cunquero
Berrocal, Alfonso
Cerezuela-Fuentes, Pablo
Fra, Pablo Luna
Peeters, Alicia Gervas
Gonzalez, Jose Luis Sanchez
Garcia, Andres Meana
Garcia, Mariasun Algarra
Garcia, Eugenio Palomares
Altozano, Javier Perez
Guerola, Monica Tallon
Maestu, Inmaculada
机构：
[1] Hosp Univ Dr Peset, Valencia, Spain
[2] Hosp Ctr Tourcoing, Tourcoing, France
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Hosp Clin Univ Valencia, INCLIVA, Valencia, Spain
[5] Unidad Canc Gipuzkoa, OSID Onkol, San Sebastian, Spain
[6] Hosp Univ Politecn La Fe, Valencia, Spain
[7] Hosp Clin Univ Virgen Arrixaca, Murcia, Spain
[8] Hosp Gen Univ Valencia, Valencia, Spain
[9] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
[10] Hosp Univ Son Espases, Palma de Mallorca, Spain
[11] Hosp Univ Doctor Peset, Valencia, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Hosp Marina Baixa, Villajoyosa, Spain
[14] Hosp Univ Vinalopo, Elche, Spain
[15] Hosp Virgen Los Lirios, Alcoy, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21529
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study
    Ochenduszko, Sebastian
    Sanchez, Javier Garcia
    Juan Fita, Maria Jose
    Gonzalez-Barrallo, Ines
    Herrero Colomina, Julio
    Mujika, Karmele
    Diaz Beveridge, Roberto
    Ros Martinez, Silverio
    Sanchez Lafuente, Blanca
    Cunquero Tomas, Alberto
    Berrocal Jaime, Alfonso
    Cerezuela Fuentes, Pablo
    Luna Fra, Pablo
    Gervas Peeters, Alicia
    Meana Garcia, Jose Andres
    Algarra Garcia, Maria Asuncion
    Perez Altozano, Javier
    Cancela, Maria
    Mateu Puchades, Almudena
    Ferrando Roca, Francisco
    Maestu Maiques, Inmaculada
    PIGMENT CELL & MELANOMA RESEARCH, 2023, 36 (05) : 388 - 398
  • [2] Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy
    Zhou, Li
    Shao, Lizhi
    Gao, Shunyu
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Yan, Xieqiao
    Wang, Xuan
    Bai, Xue
    Li, Siming
    Guo, Jun
    Si, Lu
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) : 112 - 121
  • [3] Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience
    Al jarroudi, Ouissam
    Chaabouni, Hamed
    Ulusakarya, Ayhan
    Almohamad, Wathek
    Gumus, Yusuf
    Goldschmidt, Emma
    Afqir, Said
    Morere, Jean-francois
    CLINICAL CASE REPORTS, 2021, 9 (04): : 2162 - 2167
  • [4] Understanding Real-World Patients' Experience on Pembrolizumab, Anti-Programmed Death 1 Monoclonal Antibody (Anti-PD-1), for Advanced Melanoma: A Qualitative Study
    Wong, Annie
    Billett, Alexandra
    McArthur, Grant
    Milne, Donna
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 148 - 148
  • [5] Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study
    Kato, Junji
    Namikawa, Kenjiro
    Uehara, Jiro
    Nomura, Motoo
    Nakamura, Yasuhiro
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Kiniwa, Yukiko
    Nakamura, Yoshiyuki
    Miyagawa, Takuya
    Matsushita, Shigeto
    Takenouchi, Tatsuya
    Hatta, Naohito
    Ohno, Fumitaka
    Maeda, Taku
    Fukushima, Satoshi
    Yamazaki, Naoya
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (04) : 594 - 596
  • [6] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma
    Metcalfe, Whitney
    Anderson, Jaime
    Van Anh Trinh
    Hwu, Wen-Jen
    DISCOVERY MEDICINE, 2015, 19 (106) : 393 - 401
  • [7] Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma
    Tang, Bixia
    Mo, Jiazhi
    Yan, Xieqiao
    Duan, Rong
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Kong, Yan
    Mao, Lili
    Li, Siming
    Zhou, Li
    Lian, Bin
    Wang, Xuan
    Bai, Xue
    Xu, Huayan
    Li, Caili
    Dai, Jie
    Guo, Jun
    Sheng, Xinan
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : 83 - 92
  • [8] Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population
    van Zeijl, M. C. T.
    Wouters, M. W. J. M.
    van den Eertwegh, A. J.
    Aarts, M. J.
    van Akkooi, A. C. J.
    van den Berkmortel, F. W. P. J.
    Franken, M. G.
    de Groot, J. W. B.
    Herbschleb, K. H.
    van der Hoeven, J. J. M.
    Hospers, G. A. P.
    Kapiteijn, E.
    Piersma, D.
    van Rijn, R. S.
    Suijkerbuijk, K. P. M.
    Ten Tije, A. J.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Haanen, J. B. A. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma - A Clinical Update
    Van Anh Trinh
    Joseph, Jocelyn
    Hwu, Wen-Jen
    DISCOVERY MEDICINE, 2018, 25 (135) : 31 - 40
  • [10] Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
    Cybulska-Stopa, Bozena
    Zietek, Marcin
    Kaminska-Winciorek, Grazyna
    Czarnecka, Anna M.
    Piejko, Karolina
    Galus, Lukasz
    Ziolkowska, Barbara
    Kieszko, Stanislaw
    Kempa-Kaminska, Natasza
    Calik, Jacek
    Zemelka, Tomasz
    Kubiatowski, Tomasz
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    MELANOMA RESEARCH, 2021, 31 (01) : 49 - 57
12345